Abstract: The present invention provides compositions and methods for the controlled release delivery of one or more biologically active compounds to a subject. Specifically, the invention provides for a pharmaceutical composition for the controlled release delivery of biologically active compounds to a subject comprising: a) a complex of a biologically active compound having at least one basic functional group and a polyanion derived from hexahydroxycyclohexane having at least two negatively charged functional groups; and b) a pharmaceutically acceptable carrier comprising a biodegradable, water-insoluble polymer. By complexing a biologically active compound with a polyanion, the tight, stable complex may be incorporated into a long-acting dosage system having a more desired drug release curve over time than that is found in the prior art. The invention also provides the methods of making such compositions and the methods of use thereof.

Abstract: A process for the production of CS particles (10) and microcapsules (12) is described, in which at least one active compound (4) is adsorbed in porous templates (2) (A), as a result of which templates (5) filled with active compounds are present. Subsequently, the templates (2) are provided (B) with a primer layer (6) which is intended to facilitate the subsequent construction of the capsule shell (9). The capsule shell is formed (C) by applying alternately charged polyelectrolyte layers (8). Filled CS particles (10) are obtained. By subsequent dissolution of the templates (2) the active compounds (4) are released (D) from the template into the interior of the microcapsules. The active compounds (4) remain enclosed there or are slowly released (E) from the capsule.

Abstract: The invention relates to the use of a partially neutralized, anionic (meth)acrylate copolymer comprising radically polymerized units of 25 to 95 percent by weight of C1 to C4 alkyl esters of acrylic or methacrylic acid and 5 to 75 percent by weight of (meth)acrylate monomers with an anionic group, at least 4 percent of which are neutralized by means of a base, for producing a medicament that is provided with an active substance-containing core and is coated with the partially neutralized, anionic (meth)acrylate copolymer. The medicament releases at least 30 percent of the active substance contained therein in 30 minutes at a pH at which the active substance is sufficiently soluble and stable and at which the corresponding medicament that is coated with the non-neutralized anionic (meth)acrylate polymer releases less than 10 percent of the active substance contained therein.

Abstract: The present invention relates to the use of compounds of formula (I) for the treatment of epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, or movement disorders, and to provide neuroprotection.

Abstract: Described are injectable formulations of nanoparticulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise nanoparticulate olanzapine.

Abstract: An animal model for chronic pain, and in particular lower back pain, is provided. Methods of identifying agents and reducing chronic pain with identified agents such as methotrexate are also provided.

Abstract: A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2×2.5 mg or 5 mg/day for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL is disclosed.

Abstract: A leave on hair care composition comprising a) a wax dispersion; and b) an aqueous oil emulsion wherein the oil phase is a liquid and comprises: i) one or more non-volatile oils, where the dynamic viscosity of any single non-volatile oil or the dynamic viscosity of a blend of non-volatile oils is less than 1000 mPa·s at 35° C. and 5 s-1; ii) an oil dispersible structurant such that the dynamic viscosity of the structured oil phase at 35° C. prior to formation of the emulsion is at least 50,000 mPa·s at a shear rate of 0.5 s-1 and is less than 6,000 mPa·s at a shear rate of 500 s-1.

Abstract: C-glycoside compounds having the formula (I): are useful for depigmenting/whitening the skin and/or for the anti-browning thereof.

Abstract: The invention relates to a rheological additive in the form of a preactivated paste, comprising: A) at least one fatty acid diamide introduced in powder form, it being possible for the powder optionally to comprise, in addition to the diamide, hydrogenated castor oil, B) at least one organic plasticizer, the plasticizer being liquid at room temperature. A specific process for the preparation of this rheological additive, a composition comprising the additive, a process for the preparation of the composition and specific uses, in particular specific coatings obtained from the additive, are also disclosed.

Abstract: The present invention is directed to a method for treating inflammatory arthritis in a mammal. The method typically comprises administering to an animal a therapeutically effective amount of at least one compound selected from indigo, isoindigo, indirubin or derivatives thereof, such as NATURA-? or NATURA. The present invention is further directed to pharmaceutical compositions that include a therapeutically effective amount of at least one compound of the invention, an anti-inflammatory arthritis agent and a pharmaceutically acceptable carrier.

Abstract: The invention relates to the use of octenidine dihydrochloride for manufacturing a semisolid pharmaceutical composition for the treatment of wounds, atopic dermatitides, infected eczemas, dermatomycoses, vaginal infections, acne, herpes and/or for controlling multidrug-resistant pathogens, where the composition comprises from 0.005 to 5% by weight octenidine dihydrochloride, and a corresponding composition.

Abstract: A method for producing a microfoam suitable for use in scleropathy of blood vessels comprises introducing a physiologically acceptable blood-dispersible gas into a container (1) holding an aqueous sclerosant liquid and releasing the mixture of blood-dispersible gas and sclerosant liquid, whereby upon release of the mixture the components of the mixture interact to form a microfoam.

Abstract: A method for producing a microfoam suitable for use in scleropathy of blood vessels comprises introducing a physiologically acceptable blood-dispersible gas into a container (1) holding an aqueous sclerosant liquid and releasing the mixture of blood-dispersible gas and sclerosant liquid, whereby upon release of the mixture the components of the mixture interact to form a microfoam.

Abstract: Highly durable occlusions that are useful for embolic treatment were obtained using microspheres having new combined properties of high density, low fracture, high swell capacity, rapid swell, and deformability following swell. These microspheres are provided in a microsphere powder which also has high density and high swell properties, that is prepared using a new process.

Abstract: Among cleansing cosmetics for the purpose of removing makeup, the aqueous type cleansing cosmetics containing no oil at all or a small amount of oil have had a disadvantage that remover capability is weak even though they give reduced oily feel after cleansing. The liquid oil-based makeup remover has a low viscosity so that there has been a disadvantage in usefulness that the liquid oil-based makeup remover drips off upon taking on hand. An object of the present invention is to provide a composition for cosmetics which is excellent in usefulness, has excellent affinity to makeup soil, quickly suspends soil, and is excellent in stability and rinsability.

Abstract: A hair and/or scalp treatment composition comprising an amino-oxo-indole-ylidene compound of general formula (I): (I) formula should be here in which: R1, R2, R3 and R4 are each, independently, hydrogen or a monovalent organic group selected from alkyl, alkenyl, alkynyl, aryl, alkylenearyl, cycloalkyl, cycloalkenyl, and heterocyclyl.

Abstract: A fishing lure that is water-degradable is described. The fishing lure can be a polymeric fishing lure. The fishing lure can have a body that includes vinyl resin and epoxy plasticizer, and may also include one or more of a supplemental plasticizer, heat stabilizer and/or fish attractant, and wherein the body is degradable upon immersing the body in water a body.

Abstract: The invention provides pharmaceutical compositions comprising a phenylacetic acid ester compound useful for inducing or maintaining general anesthesia or sedation in mammals, methods for preparing such compositions, and methods for inducing or maintaining anesthesia or sedation using such compositions.

Abstract: A C-nitroso moiety derived from a carbon acid with a pKa less than about 25 is bound in a biocompatible polymer as an ester or ether to a pendant hydroxyl group, as an ester to a pendant carboxylic acid or as an amine or amide to a pendant amine moiety. The polymer with c-nitroso moiety bound thereto can be coated on a medical device and/or used for prophylaxis of a patient at risk for restenosis. A c-nitroso moiety bound as amide to polyisobutylene amine substituted styrene copolymer is described in detail.